Epigral Limited has informed the Exchange about Investor Presentation
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Epigral Limited reported record Q4FY26 revenue of ₹736 crore, up 22% QoQ driven by 15% sequential volume growth and improved plant utilization above 80%. EBITDA margin recovered to 23% in Q4 from 17% in Q3 due to better utilization and normalized raw material costs. For full year FY2026, revenue stood at ₹2,542 crore (down 1% YoY), EBITDA at ₹567 crore (22% margin), and adjusted PAT at ₹252 crore excluding a one-time ₹81 crore deferred tax benefit. ROCE declined to 16% from 25% due to lower utilization, higher capex activity, and increased raw material prices. The company spent ₹394 crore on capex in FY2026, with expansion plans for CPVC Resin (to 150,000 TPA) and Epichlorohydrin (to 100,000 TPA) on track for H1FY27 commissioning. Revenue from Derivatives & Specialty Chemicals reached 54% in Q4, with management targeting ~70% by FY2028. The board proposed a dividend of ₹5 per share.
Positive signals include margin recovery, strong volume growth momentum, and capex execution on schedule. However, FY2026 full-year performance was impacted by monsoon and maintenance, with Net Debt/EBITDA rising to 0.9x. The upcoming H1FY27 capacity expansions position the company for improved profitability if demand conditions remain favorable.